Nanion Technologies and NEXEL partner to open a new reference
demonstration laboratory in South Korea
Munich, Germany, April 17th 2020: Nanion Technologies GmbH, a leading provider of automatedpatch clamp and cell monitoring systems, announces the partnership with NEXEL Co., Ltd.,
specialists in the manufacturing of hiPSC-derived cells. Under the partnership NEXEL will provide
demonstration infrastructure in South Korea for Nanion´s CardioExcyte 96 and FLEXcyte 96 cell
monitoring systems, while Nanion will provide scientific proficiency in experimental design andassay development.

Nanion Technologies and NEXEL are pleased toannounce a partnership, focused on combining Nanion’s
CardioExcyte 96 and FLEXcyte 96 cell monitoring
technology with NEXEL’s hiPSC-derived cells fordemonstration purposes. Bringing together the twocompanies’ infrastructure and expertise serves to meetthe growing demand for a reliable, high throughput cell
monitoring technology in Asia.
The Nanion-NEXEL partnership brings together profoundskills in comprehensive in vitro electrophysiology
technology and development of human induced
pluripotent stem cells (hiPSCs), with focus on
cardiomyocytes. Under the partnership, NEXEL opens areference demonstration laboratory for Nanion´s systems
at NEXEL’s headquarters in Seoul, whereby bothcompanies aim to significantly upscale support of theirclients in Asia.

Dr. Choong-Seong Han, CEO of
Nexel, says: “Nexel is proud to start
this partnership with Nanion
Technologies. We believe it willfurther build on the excellent
relationship we have developed
together in the last year. The
Cardiosight®-S
cardiomyocytes
have been fully validated on theCardioExcyte 96 and FLEXcyte 96
systems and our expert scientistsare dedicated to provide the best demo settings as wellas product experience for customers, as part of thecollaboration. We hope interest in both Nanion’s andNEXEL’s offerings will increase with our collaborativeefforts.”

The CardioExcyte 96 and its add-on FLEXcyte 96 enable a comprehensive
analysis of viability, contractility and electrophysiology of cardiomyocyte
networks under physiological conditions. This allows diverse assay
applications, such as safety pharmacology, basic cardiotox assays anddrug discovery assays. In addition, FLEXcyte 96 offers recordings on flexiblesubstrates which allow monitoring true contractility under physiologicalconditions.

Frank Henrichsen, Director of
GlobalSalesofNanion
Technologies adds: “We are veryeager to strengthen our position in
the Asian market and especially in
Korea. In NEXEL, we see a valuble
partner to help us develop ourpresence, in this case throughopening their laboratories andenabling the use of Nanion´stechnology for demo purposes attheir premises. Combining NEXEL´s hiPSC-derived
cardiomyocytes and cardiac in vitro assays with Nanion’s
CardioExcyte 96 and FLEXcyte 96 systems, we areconfident that our customers will get an excellent
package solution for use in safety pharmacology andtoxicology assays . We are also very happy that NEXEL has
already implemented the systems into their quality control
procedure of Cardiosight®-S cardiomyocytes.”About Nanion Technologies:

About NEXEL:

Nanion Technologies is a leading provider ofinstrumentation for ion channel drug discovery andscreening. Founded in 2002, Nanion has grown over thelast 18 years to a company with over 100 employees
worldwide. With headquarters in Munich, Germany,
Nanion has subsidiaries in the USA, Japan, China andDenmark, as well as distribution partners in seven othercountries.

NEXEL, Co., Ltd. is a bio-company that was incorporated
in 2012 with proprietary stem cell technologies. Theirphilosophy is to “make a better place” by supporting
innovative research around the globe by providing highquality stem cell-derived cell products.

Nanion’s team has developed and successfully
established four generations of automated patch clamp
instruments for sophisticated and high throughput
applications in ion channel research and drug discovery(Port-a-Patch, Patchliner and SyncroPatch productfamilies).
Further product lines are for cell monitoring andcardiotoxicity screening (CardioExcyte 96/FLEXcyte 96),
for parallel bilayer recordings (Orbit family), and forparallel membrane transporter protein recordings(SURFE²R).

NEXEL, Co., Ltd. launched the Cardiosight®-S in 2018
which has since been validated on multiple platforms as
a pure and functional population of hiPSC-derived
cardiomyocytes. Their focus is providing an optimized user
experience by performing extensive testing on theplatform used by our users, e.g. cardiac safety
pharmacology on the CardioExcyte 96.
Other product lines include the Hepatosight ®-S (iPSderived hepatocytes) and the Neurosight ®-S (iPS-derivedneurons).

For more information, please visit: www.nanion.de

For more information, please visit: www.nexel.co.kr

Contact:

Contact:

Quantum Design Korea
Nanion Technologies official distributor in Republic ofKorea

Jeong-Wook Kim, CSMONEXEL Co. Ltd.

e-mail: mwnam@qdkorea.com
web: www.qdkorea.com

e-mail: sales@nexel.co.kr
web: www.nexel.co.kr